Pharma BD Deal Intelligence
Bayer to acquire BlueRock Therapeutics for up to $600M with cell therapy pipeline in mind including Parkinson disease candidate
Bayer acquires BlueRock Therapeutics in cell therapy move gaining full rights to proprietary CELL GENE iPSC platform technology
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Bayer acquired remaining 60% stake in BlueRock Therapeutics for ~$600M.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / BlueRock Therapeutics (this deal) | 2002 | $600M | 79 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2002 deals · Bayer AG deals · Cardiovascular deals